U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Mg.O
Molecular Weight 40.3044
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Magnesium oxide

SMILES

[O--].[Mg++]

InChI

InChIKey=AXZKOIWUVFPNLO-UHFFFAOYSA-N
InChI=1S/Mg.O/q+2;-2

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/dosage/magnesium-lactate.htmlhttps://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.ncbi.nlm.nih.gov/pubmed/351265https://www.drugs.com/ppa/magnesium-chloride.htmlhttp://www.db-pharma.com/anglais/49.pdfhttps://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1http://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfdoi: 10.1081/SCC-120022479DOI: 10.2903/j.efsa.2008.883https://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640
Curator's Comment: description was created based on several sources, including: https://www.blackmores.com.au/products/magmin | https://www.ncbi.nlm.nih.gov/pubmed/25262412 |http://www.webstercare.com.au/files/continuing_education/wc_continuing_edu_dec2011.pdf

Magnesium diamide is used as a chemical intermediate. Magnesium diamide is spontaneously combustible. It is toxic by inhalation. Skin or eye contact may cause severe burns.

CNS Activity

Originator

Ulex, G.L.
66
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Modulator
846
Modulator
846
Modulator
846
Modulator
846
Interacts
323
Protein S100-A8
66
Target ID: P05109
Gene ID: 6279.0
Gene Symbol: S100A8
Target Organism: Homo sapiens (Human)
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Preventing
Approved
8583
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Primary
Approved
8583
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Diagnostic
Approved
8583
ColPrep Kit

Approved Use

INDICATIONS AND USAGE ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults

Launch Date

2016
Primary
Phase III
665
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Curative
Approved
8583
MagMin

Approved Use

Magnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia.
Curative
Not Provided
511
DELBIASE

Approved Use

Unknown
Primary
Not Provided
511
DELBIASE

Approved Use

Unknown
Primary
Not Provided
511
DELBIASE

Approved Use

Unknown
Curative
Approved
8583
Magnesium Chloride

Approved Use

Magnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies
Palliative
Phase II
1147
Magnesium Chloride

Approved Use

Unknown
Palliative
Phase III
665
Magnesium Chloride

Approved Use

Unknown
Primary
Approved
8583
EPIMAG

Approved Use

Magnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones.
Primary
Approved
8583
EPIMAG

Approved Use

Used to relief of occasional constipation (irregularity).
Curative
Approved
8583
Magnesium Citrate

Approved Use

Magnesium citrate is indicated to supports magnesium nutritional adequacy.
Curative
Approved
8583
Unknown

Approved Use

Magnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency.
PubMed

PubMed

TitleDatePubMed
Antenatal Exposure to Magnesium Sulfate and Spontaneous Intestinal Perforation and Necrotizing Enterocolitis in Extremely Preterm Neonates.
2017-10
Fast sono assisted ferrofluid mediated silver super - Adsorption over magnesium ferrite-copper sulfide chalcogenide with the aid of multivariate optimization.
2017-07
Effect of power ultrasound on crystallization characteristics of magnesium ammonium phosphate.
2017-05
Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes.
2017-03-01
Superiority of a Split-dose Regimen of Sodium Picosulfate/Magnesium Citrate (SPMC) in Comparison to a Prior-day Schedule (AM/PM) for Colonoscopy Preparation. A Randomized Single-blinded Study.
2016-09
Preparation and optimization of a drug delivery system based on berberine chloride-immobilized MgAl hydrotalcite.
2016-06-15
Polyethylene glycol plus ascorbic acid is as effective as sodium picosulfate with magnesium citrate for bowel preparation: A randomized trial.
2016-04
Micronized Organic Magnesium Salts Enhance Opioid Analgesia in Rats.
2016
Single-day sodium picosulfate and magnesium citrate versus split-dose polyethylene glycol for bowel cleansing prior to colonoscopy: A prospective randomized endoscopist-blinded trial.
2015-11
Randomized controlled trial of low-volume bowel preparation agents for colonic bowel preparation: 2-L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate.
2015-02
A comparison of oral sulfate solution with sodium picosulfate: magnesium citrate in split doses as bowel preparation for colonoscopy.
2014-12
No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia.
2014-09-10
Precipitation of amorphous magnesium ammonium phosphate: is it a precursor for staghorn stones?
2014-06
Effects of three kinds of organic acids on phosphorus recovery by magnesium ammonium phosphate (MAP) crystallization from synthetic swine wastewater.
2014-04
[The effectiveness of certain magnesium salts in nephrolithiasis caused by the use of sodium oxalate and celecoxib].
2013-05-14
Effect of magnesium lactate dihydrate and calcium lactate monohydrate on 20-km cycling time trial performance.
2012-04
Magnesium chloride tetrahydrate, MgCl2·4H2O.
2012-01
Increased expression of glucose transporter 3 in gerbil brains following magnesium sulfate treatment and focal cerebral ischemic injury.
2010-06
Intradermal administration of magnesium sulphate and magnesium chloride produces hypesthesia to mechanical but hyperalgesia to heat stimuli in humans.
2009-08-28
Formation of formal disilene fluoride adducts.
2008-12-24
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
2006-04
Synthesis of a non-heme template for attaching four peptides: an approach to artificial iron(II)-containing peroxidases.
2004-01-23
Magnesium bromide mediated highly diastereoselective heterogeneous hydrogenation of olefins.
2002-04-18
Oral magnesium load test in patients with migraine.
2002-02
Bioavailability of US commercial magnesium preparations.
2001-12
Trifluoromethanesulfonic anhydride-promoted alpha-bromination of ketones with grignard reagent or magnesium bromide.
2000-12
An efficient chiral moderator prepared from inexpensive (+)-3-carene: synthesis of the HIV-1 non-nucleoside reverse transcriptase inhibitor DPC 963.
2000-10-05
Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by 31P-NMRS and ion selective electrodes.
1999-11
Some magnesium salts and a mixture of magnesium and calcium salts accelerate skin barrier recovery.
1999-10
Struvite stones.
1999
Magnesium supplementation in patients with congestive heart failure.
1997-02
Conventional and Eccentric Uses of Crystallographic Databases in Practical Materials Identification Problems.
1996-01-01
Inhibition of mouse-killing behaviour in magnesium-deficient rats: effect of pharmacological doses of magnesium pidolate, magnesium aspartate, magnesium lactate, magnesium gluconate and magnesium chloride.
1995-03
Effect of pyridoxine and magnesium on stress-induced gastric ulcers in mice selected for low or high blood magnesium levels.
1995
Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity.
1995
A prospective randomized trial of intravenous magnesium versus intravenous propranolol in acute myocardial infarction.
1994-12
Accidental cardiopulmonary arrest following magnesium sulphate overdose.
1994-06-15
Management of eclampsia.
1994-04
Oral versus intravenous magnesium supplementation in patients with magnesium deficiency.
1991-01-01
Magnesium and its combination with cinnarizine in the long-term treatment of headache.
1991
Osteoporosis treated with magnesium lactate.
1991
Fluorimetry of selenium in body fluids after digestion with nitric acid, magnesium nitrate hexahydrate, and hydrochloric acid.
1988-09
A comparison of two digestion procedures for the determination of selenium in biological material.
1987-10
Metabolism of magnesium and zinc in patients treated with antiepileptic drugs and with magnesium lactate.
1987
Effects of the intravenous administration of magnesium sulfate on corrected serum calcium level and nephrogenous cyclic AMP excretion in normal human subjects.
1986-11
Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides.
1986-03-22
[Inhibitory effect of magnesium on the vocalization and fighting of cats treated with carbachol and eserine].
1982
Cardiopulmonary arrest due to acute maternal hypermagnesaemia.
1981-05-09
Struvite stones.
1978-05
Metabolic effects of prolonged intravenous administration of magnesium lactate to the normal human.
1958-09-23
Patents

Patents

03931199
72
03931205
77
03931302
69
03932463
70
03932472
89
03932479
113
03932483
75
03932524
68
03933824
70
03935253
66
03935271
69
03936470
98
03939091
68
03944589
66
03950406
119
03950427
70
03950525
67
03957788
66
03960906
66
03960907
67
03961066
66
03963724
66
03965143
66
03966648
67
03966773
135
03968231
67
03969368
66
03969384
66
03973022
77
03973030
67
03978121
74
03978129
66
03978130
66
03980795
66
03981917
74
03982001
66
03983164
67
03985729
66
03985817
66
03987009
96
03987091
67
03988205
66
03989724
72
03989749
68
03989841
66
03991106
66
03993773
66
03994961
66
03995054
67
03995056
70
03998834
70
04005147
106
04045433
67
04059595
66
04088772
67
04144333
66
04156786
66
04289816
66
04341767
67
04454357
66
04471070
66
04540815
66
04546195
66
04569941
66
04577011
67
04585885
67
04599341
66
04661260
68
04725688
68
04734420
74
04916235
70
04935430
66
04990319
66
05012019
66
05177240
66
05206229
66
05275950
67
05326548
66
05389640
67
05451591
67
05633237
66
05658908
68
05719148
82
05786353
67
05859290
66
05929067
67
06017928
73
06040331
66
06051712
73
06100275
67
06150526
73
06156767
66
06274737
68
06380218
73
06540905
67
06613708
66
06812355
66
07230017
69
07402595
70
07445915
66
07557213
67
07601736
66
07691842
69
08236943
66
08383835
66
20050130276
66
20060100207
66
20100267970
66
CN106582743
66
DE1110825
66
EP1810974A1
66
EP2259773A1
66
EP2708510A1
66
EP2714042A1
66
US1913539
66
US20060083725
66
US20140076804
66
US2034070
66
US2260004
66
US2877095
66
US3030184
66
US3320048
66
US3377271
66
US3429777
66
US3476510
66
US3760050
66
US3994859
66
US4111835
66
US4535183
66
US4748283
66
US4959222
66
US7182872
66
US7608239
66
US9334166
66
WO2000050046A1
66
WO2005123647A1
68

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Magnesium Chloride
Magnesium lactate is used as a dietary supplement (200-400 mg of elemental magnesium per day for adults).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Magnesium Chloride
Unknown
Name Type Language
Magnesium oxide
FCC   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
HEAVY MAGNESIUM OXIDE
WHO-IP  
Preferred Name English
MAGNESIUM OXIDE, LIGHT [EP MONOGRAPH]
Common Name English
MAGNESIUM OXIDE, HEAVY [EP MONOGRAPH]
Common Name English
MAGNESIUM OXIDE, LIGHT
EP   II  
Common Name English
MAGNESIUM OXIDE [MI]
Common Name English
MAGNESIUM OXIDE [VANDF]
Common Name English
MAGNESIUM OXIDE [USP-RS]
Common Name English
MAGNESIUM OXIDE HEAVY [WHO-DD]
Common Name English
MAGNESIA [VANDF]
Common Name English
MAGNESIUM OXIDE [FCC]
Common Name English
MAGNESIUM OXIDE [MART.]
Common Name English
MAGNESIUM OXIDE [ORANGE BOOK]
Common Name English
MAGNESIA OXYDATA
HPUS  
Common Name English
MAGNESIUM OXIDE [JAN]
Common Name English
INS-530
Code English
INS NO.530
Code English
CLENPIQ COMPONENT MAGNESIUM OXIDE
Brand Name English
MAGNESIUM OXIDE, LIGHT [II]
Common Name English
MAGNESII OXIDUM [WHO-IP LATIN]
Common Name English
MAGNESIUM OXIDE [WHO-IP]
Common Name English
MAGNESIUM OXIDE, HEAVY
EP  
Common Name English
MAGNESIUM OXIDE [USP MONOGRAPH]
Common Name English
MAGNESIA OXYDATA [HPUS]
Common Name English
MAGNESIUM OXIDE [WHO-DD]
Common Name English
MAGNESIUM OXIDE [II]
Common Name English
LIGHT MAGNESIUM OXIDE [WHO-IP]
Common Name English
E-530
Code English
MAGNESIUM OXIDE, HEAVY [EP IMPURITY]
Common Name English
MAGNESIUM OXIDE [HSDB]
Common Name English
MAGNESIUM (AS OXIDE) [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QA02AA02
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
JECFA EVALUATION INS-530
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
CFR 21 CFR 331.15
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
WHO-ATC A12CC10
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
NCI_THESAURUS C29697
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-530
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
WHO-VATC QA06AD02
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
CFR 21 CFR 331.11
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
WHO-ATC A02AA02
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
CFR 21 CFR 176.170
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
WHO-ATC A06AD02
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
CFR 21 CFR 184.1431
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
WHO-VATC QA12CC10
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
CFR 21 CFR 178.3297
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
Code System Code Type Description
EVMPD
SUB12130MIG
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
CAS
1309-48-4
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
DAILYMED
3A3U0GI71G
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
MESH
D008277
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-171-9
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
NCI_THESAURUS
C29242
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
RXCUI
6582
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY RxNorm
DRUG CENTRAL
4293
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
HSDB
1652
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200572
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
EVMPD
SUB14436MIG
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
CONCEPT Dietary Supplement
EVMPD
SUB12129MIG
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
EPA CompTox
DTXSID9049665
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
FDA UNII
3A3U0GI71G
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
LACTMED
Magnesium Oxide
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
SMS_ID
100000087594
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
MAGNESIUM OXIDE
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY Description: A white powder; odourless. Light Magnesium oxide is very bulky, whereas heavy Magnesium oxide is a dense powder. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Antacid. Storage: Magnesium oxide should be kept in a tightly closed container.Labelling: The designation on the container should state whether it is light Magnesium oxide or heavy Magnesium oxide.Definition: Magnesium oxide contains not less than 98.0% and not more than 100.5% of MgO, calculated with reference to the ignited substance.
WIKIPEDIA
MAGNESIUM OXIDE
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
RS_ITEM_NUM
1374281
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
CHEBI
31794
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
DRUG BANK
DB01377
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
PUBCHEM
6850729
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY
MERCK INDEX
m7011
Created by admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
PRIMARY Merck Index
SUBSTANCE RECORD
Structure of Magnesium oxide
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966